Dermata Stock Today

DRMA -  USA Stock  

USD 2.45  0.27  9.93%

Market Performance
0 of 100
Odds Of Distress
Over 62
Dermata Therapeutics is trading at 2.45 as of the 1st of December 2021, a -9.93% down since the beginning of the trading day. The stock's open price was 2.72. Dermata Therapeutics has more than 62 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Dermata Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of October 2021 and ending today, the 1st of December 2021. Click here to learn more.

Dermata Therapeutics Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Dermata Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Dermata Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Dermata Therapeutics generated a negative expected return over the last 90 days
Dermata Therapeutics has high historical volatility and very poor performance
Dermata Therapeutics has high likelihood to experience some financial distress in the next 2 years
Dermata Therapeutics was previously known as Dermata Therapeutics and was traded on NASDAQ Exchange under the symbol DRMAW.
Dermata Therapeutics has a frail financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Dermata Therapeutics exotic insider transaction detected
Dermata Therapeutics Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Dermata Therapeutics SEC Filings
Dermata Therapeutics SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameDermata Therapeutics
Older SymbolDRMAW
Average Analyst Recommendation
Analysts covering Dermata Therapeutics report their recommendations after researching Dermata Therapeutics' financial statements, talking to executives and customers, or listening in on Dermata Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Dermata Therapeutics. The Dermata consensus assessment is calculated by taking the average forecast from all of the analysts covering Dermata Therapeutics.
Strong Buy2 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Dermata Therapeutics based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Dermata Therapeutics financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 2 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares1.7 M1.7 M
Slightly Down
Slightly volatile
Weighted Average Shares Diluted1.7 M1.7 M
Slightly Down
Slightly volatile
Total Assets881 K605.5 K
Way Up
Slightly volatile
Total Liabilities3.7 M3.8 M
Fairly Down
Slightly volatile
Current Assets881 K605.5 K
Way Up
Slightly volatile
Current Liabilities3.6 M3.8 M
Notably Down
Slightly volatile
Total Debt3.3 M3.5 M
Significantly Down
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Dermata Therapeutics' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Cautious HoldUndervalued
Financial Strength
Dermata Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Dermata Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dermata Therapeutics' financial leverage. It provides some insight into what part of Dermata Therapeutics' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Dermata Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Dermata Therapeutics deploys its capital and how much of that capital is borrowed.
Dermata Therapeutics (DRMA) is traded on NASDAQ Exchange in USA. It is located in null . Dermata Therapeutics was previously known as Dermata Therapeutics and was traded on NASDAQ Exchange under the symbol DRMAW. Dermata Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company conducts business under Healthcare sector and is part of Biotechnology industry.
Check Dermata Therapeutics Probability Of Bankruptcy

Dermata Stock Price Odds Analysis

What are Dermata Therapeutics' target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Dermata Therapeutics jumping above the current price in 90 days from now is close to 99%. The Dermata Therapeutics probability density function shows the probability of Dermata Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.108 suggesting Dermata Therapeutics market returns are sensitive to returns on the market. As the market goes up or down, Dermata Therapeutics is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Dermata Therapeutics is significantly underperforming DOW.
 Odds Down 2.45HorizonTargetOdds Up 2.45 
0.43%90 days
Based on a normal probability distribution, the odds of Dermata Therapeutics to move above the current price in 90 days from now is close to 99 (This Dermata Therapeutics probability density function shows the probability of Dermata Stock to fall within a particular range of prices over 90 days) .

Dermata Therapeutics Historical Income Statement

Dermata Therapeutics Income Statement is one of the three primary financial statements used for reporting Dermata's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Dermata Therapeutics revenue and expense. Dermata Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
View More Fundamentals

Dermata Stock Against Markets

Picking the right benchmark for Dermata Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Dermata Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Dermata Therapeutics is critical whether you are bullish or bearish towards Dermata Therapeutics at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Dermata Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Commodity Channel Index Now


Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Module
Continue to Investing Opportunities. Note that the Dermata Therapeutics information on this page should be used as a complementary analysis to other Dermata Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Is Dermata Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Dermata Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.